Cypress Asset Management Inc. TX acquired a new stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 5,157 shares of the medical instruments supplier's stock, valued at approximately $1,194,000.
A number of other large investors have also added to or reduced their stakes in the company. Wesbanco Bank Inc. lifted its stake in Becton, Dickinson and Company by 1.9% during the 4th quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier's stock valued at $580,000 after acquiring an additional 48 shares during the period. S.A. Mason LLC boosted its holdings in Becton, Dickinson and Company by 3.7% in the fourth quarter. S.A. Mason LLC now owns 1,414 shares of the medical instruments supplier's stock valued at $321,000 after purchasing an additional 50 shares during the last quarter. Hillsdale Investment Management Inc. grew its position in Becton, Dickinson and Company by 1.7% during the 4th quarter. Hillsdale Investment Management Inc. now owns 3,060 shares of the medical instruments supplier's stock worth $694,000 after purchasing an additional 50 shares during the period. Americana Partners LLC raised its stake in shares of Becton, Dickinson and Company by 3.5% during the 4th quarter. Americana Partners LLC now owns 1,520 shares of the medical instruments supplier's stock valued at $345,000 after buying an additional 52 shares during the last quarter. Finally, Picton Mahoney Asset Management lifted its holdings in shares of Becton, Dickinson and Company by 61.4% in the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock valued at $32,000 after buying an additional 54 shares during the period. Institutional investors own 86.97% of the company's stock.
Analyst Ratings Changes
BDX has been the topic of several research analyst reports. Piper Sandler lowered shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and dropped their target price for the company from $260.00 to $185.00 in a research report on Friday, May 2nd. The Goldman Sachs Group lowered Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price objective on the stock. in a report on Friday, May 2nd. Bank of America lowered shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 target price for the company. in a report on Thursday, May 1st. William Blair lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research report on Thursday, May 1st. Finally, Wells Fargo & Company downgraded shares of Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a report on Thursday, May 1st. Eight equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $221.44.
Check Out Our Latest Stock Report on Becton, Dickinson and Company
Insider Buying and Selling
In other news, EVP Richard Byrd sold 459 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $230.00, for a total value of $105,570.00. Following the completion of the transaction, the executive vice president now owns 6,952 shares of the company's stock, valued at approximately $1,598,960. This trade represents a 6.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 479 shares of the stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the sale, the executive vice president now owns 4,887 shares in the company, valued at approximately $964,107.36. This trade represents a 8.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 2,878 shares of company stock valued at $636,393. Company insiders own 0.36% of the company's stock.
Becton, Dickinson and Company Trading Down 0.5%
BDX stock traded down $0.84 during trading on Friday, reaching $172.98. 949,274 shares of the stock were exchanged, compared to its average volume of 1,929,546. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $49.58 billion, a price-to-earnings ratio of 28.73, a P/E/G ratio of 1.63 and a beta of 0.31. The business has a 50 day moving average price of $193.74 and a 200-day moving average price of $217.14. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, beating analysts' consensus estimates of $3.28 by $0.07. The firm had revenue of $5.27 billion for the quarter, compared to analysts' expectations of $5.35 billion. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. The firm's quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the firm posted $3.17 earnings per share. On average, research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.
Becton, Dickinson and Company Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Stockholders of record on Monday, June 9th will be paid a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.40%. The ex-dividend date of this dividend is Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 79.39%.
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Stories
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
